Gilead Sciences (NASDAQ:GILD) has been working
with regulatory authorities to start additional expanded access
programs for remdesivir, its investigational medicine for COVID-19,
Chairman and CEO Daniel O’Day wrote on the company’s website.
Such programs allow hospitals or physicians to
apply for emergency use of the treatment for multiple severely ill
patients at a time.
Even though the medicine isn’t yet approved for
use by any regulatory authorities, Gilead is taking the step of of
expanding production to increase supply.
“As a result we have reduced the end-to-end
manufacturing timeline from approximately one year, to around six
months,” O’Day wrote.
Its existing supply, including finished product
and investigational medicine in final stages of production, amounts to
1.5M individual doses, which could equate to more than 140,000 treatment
courses for patients.
Gilead is providing all of its existing supply at no cost to treat patients with the most severe symptoms of COVID-19.
Sets a goal of producing more than 500,000
treatment courses by October and more than 1M treatment courses by the
end of the year.
Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, has recommended
that in order to be prepared for COVID-19 becoming a seasonal
occurrence, drug manufacturers should take the risk to ramp up
production of therapeutics before phase 2 trials begin.
Previously: Gilead’s remdesivir OK’d in Europe for compassionate use in COVID-19 (April 3)
https://seekingalpha.com/news/3558442-gilead-ramps-up-remdesivir-production-ahead-of-approvals
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.